Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We have described a murine model of IBD that was induced in C.B-17 scid mice by transfer of the CD45RBhi subpopulation of CD4+ T cells from normal BALB/c mice and could be prevented by cotransfer of the CD45RBlo CD4+ T cell subset. Here we have dissected the mechanism of pathogenesis of IBD in this model and used this information for rational immunotherapy of the disease. CD4+ cells from diseased mice displayed a highly polarized Th1 pattern of cytokine synthesis upon polyclonal stimulation in vitro. The administration of anti-IFN gamma MAb to mice soon after T cell transfer prevented development of colitis for up to 12 weeks. Continual neutralization of TNF with anti-TNF MAbs reduced the incidence of severe disease; however, neutralization of TNF during only the first 3-4 weeks had no effect. Severe colitis was completely abrogated in mice treated systemically with rIL-10, but not with rIL-4.

Original publication

DOI

10.1016/1074-7613(94)90045-0

Type

Journal article

Journal

Immunity

Publication Date

10/1994

Volume

1

Pages

553 - 562

Keywords

Animals, Antibodies, Monoclonal, CD4-Positive T-Lymphocytes, Colitis, Colon, Inflammatory Bowel Diseases, Interferon-gamma, Interleukins, Leukocyte Common Antigens, Mice, Mice, Inbred BALB C, Mice, SCID, Models, Immunological, RNA, Messenger, T-Lymphocyte Subsets, Th1 Cells, Time Factors, Tumor Necrosis Factor-alpha